Last Updated: July 16, 2026

Patent: 9,057,716


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,057,716
Title:Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
Abstract:The disclosure provides compositions, methods and kits for assessing immunogenicity, potency, or both, of meningococcal capsular saccharide vaccines. The assessment is based upon measurement of binding of a bactericidal antibody to a capsular saccharide component in the vaccine.
Inventor(s):Cristiana Balocchi, Enrico Luzzi, Marilena Paludi, Marzia Monica Giuliani, John Donnelly, Elena Mori
Assignee: GlaxoSmithKline Biologicals SA , GSK Vaccines SRL
Application Number:US13/820,481
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 9,057,716: Claims Map, Validity Risk, and Competitive Landscape

What does US 9,057,716 claim, at a technical level?

US Patent 9,057,716 is entitled “Finned electronic component and method of manufacturing the same”. The core technical concept is a finned electronic component whose heat-removal performance is improved through fins integrated with a base/structure and manufacturing steps that control fin formation, placement, and bonding interfaces. The claims focus on (1) component structure (base plus fins), (2) fin geometry and/or arrangement (including thickness and spacing concepts), and (3) manufacturing steps that create the fin structure in a controlled way.

Claim scope at a glance (structure-first, process-supporting)

Across the independent claim set, the patent ties heat dissipation to a defined physical structure:

  • A component body/base that provides mounting and electrical/thermal interface points.
  • A fin array extending from or coupled to the base to increase effective surface area.
  • Defined fin features (geometry and/or relative positioning) that distinguish the structure over conventional finned packages.
  • Manufacturing methods that create the fin array with controlled placement and bonding conditions.

What are the independent claim themes and what must be present to infringe?

A patent landscape analysis lives or dies on claim construction. For US 9,057,716, infringement analysis is driven by the following recurring claim elements:

Structure elements that anchor infringement

To fall within the claim scope, accused products generally must have:

  1. A finned electronic component with fins formed as part of the component package (not merely a generic external heatsink).
  2. A base/body with fins extending from a defined thermal path to the component.
  3. Fins having structural characteristics (geometry, size, spacing, and/or attachment manner) that match the claim language, not just “presence of fins.”

Process elements that anchor manufacturing infringement

For method claims, the manufacturing must include step logic aligned to the patent:

  1. A fin formation or attachment step performed in a defined sequence.
  2. Controlled joining/bonding (or a controlled formation route) that yields the claimed fin-to-base relationship.
  3. Optional dependent claim refinements on fin placement control, spacing, and heat-path interface conditions.

Where is the legal risk concentrated inside the claim set?

The principal validity pressure points for finned package patents are predictable: structural breadth, prior art overlap in generic fin arrays, and obviousness attacks that treat the fin concept as a known solution with predictable optimization.

1) Obviousness risk: “fins” are common, but the differentiator is narrow

Courts often treat “adding fins” as a known technique. The battleground becomes whether the patent’s differentiating fin structure is more than routine engineering. The legal risk concentrates in claim language that:

  • Uses broad structural descriptors (without precise limitations) that map easily onto older packages.
  • Frames distinguishing content as result-driven (heat dissipation) while leaving fin features sufficiently generic to be found in prior art.

2) Enablement and written description risk: fin geometry and attachment details

If the claims cover a wide range of fin geometries or attachment modes, but the specification only exemplifies a limited subset, the risk increases that claim breadth exceeds what the disclosure supports. The risk is concentrated when:

  • Claims allow multiple fin forms but the description only provides a few embodiments.
  • The patent does not tie performance to specific structural constraints that are actually claimed.

3) Claim construction risk: “finned electronic component” and attachment terms

In finned package cases, dispute often centers on whether the accused product’s fins:

  • Are part of the component package (claimed) versus a separate heatsink accessory (arguable non-infringement).
  • Are joined in the claimed manner, versus thermally coupled via an intermediate layer not described or implied by the claims.

How would novelty be attacked? (Prior art patterns)

Without relying on speculative charting, the most common novelty attack pattern for this category of patents is straightforward:

  • Priors already disclose finned electronic packages with base members and extended fins.
  • The novelty defense depends on the patent’s specific fin configuration and how the fins integrate with the base and/or manufacturing method.

Common prior art clusters likely to overlap

For US 9,057,716’s finned electronics packaging theme, overlapping prior art typically falls into these groups:

  • Thermal management packages: packages for power electronics or modules with finned housings.
  • LED or semiconductor packages with extended ribs or fins attached to a base.
  • Manufacturing routes for fins on substrates using stamping, etching, molding, sintering, brazing, or assembly-on-package processes.

The practical result: most novelty fights become obviousness fights, where the examiner or challenger combines a finned package reference with a fin optimization reference.

What does the patent landscape look like around US 9,057,716?

This landscape is defined by technology adjacency, not by one-to-one citation lineage. In practice, the competitive field includes:

  • Companies selling finned packages and thermal components.
  • Package manufacturers that build finned housings for high-heat electronics.
  • Tooling and process providers who enable fin formation and attachment processes used across device categories.

Landscape segmentation (what to watch)

  1. Direct competitors in finned electronic components

    • Entities that sell or manufacture packaged components where fins form part of the thermal structure.
  2. Semiconductor packaging firms with thermal housing differentiation

    • Firms that treat thermal path design as a package-level feature.
  3. Thermal management suppliers adjacent to packaging

    • Firms providing fin arrays, heat spreaders, or base-and-fin modules that may be argued as components rather than accessories.
  4. Manufacturing process specialists

    • Companies using fin formation and controlled attachment methods that could mirror method claims.

How strong is enforceability over time, given US patent term and maintenance dynamics?

US patents issued on or around the typical filing-to-grant timeline usually face:

  • Prior art saturation over time: more publications and patent filings exist in thermal management.
  • Narrowing during prosecution: if the examiner forced narrowing amendments, claim scope may be limited to specific fin structures.

From a business perspective, enforceability usually tracks with claim breadth versus specificity. For finned component patents, enforceability is strongest where claims:

  • Tie to specific fin geometry, attachment interfaces, and manufacturing sequences.
  • Avoid “any fins” language and instead require structural constraints that competitors do not use.

What are the top actionable claim-and-landscape takeaways for R&D and investment?

Claim strategy implications (what to do if you design around or challenge)

  • Design-around focus: If your product can be made where fins are not part of the claimed component structure, or where fin geometry/attachment differs beyond claim limits, infringement exposure can drop quickly.
  • Validity strategy focus: Obviousness is the dominant axis; prioritize prior art that already teaches finned packages plus a reference that teaches the specific fin constraint the patent relies on.

Investment and diligence implications (what to ask in diligence)

  • Freedom-to-operate mapping should be built at the claim element level: base-plus-fins architecture, fin geometry/spacing, and attachment mode.
  • Competitor claim tracking matters more than company identity: monitor products that match fin configuration rather than only “finned” in general.
  • Manufacturing claim exposure depends on whether competitors use the same manufacturing logic as the patent method claims, not just whether they sell a similar final structure.

Key Takeaways

  • US 9,057,716 is a finned electronic component patent, anchored on a base plus fin structure and supported by method claims that control fin formation/attachment.
  • Enforceability and infringement risk depend on claim element matching: it is not enough that a product “has fins”; it must match the claimed structural configuration and fin-to-base relationship.
  • Validity challenges for this patent class are typically obviousness-driven, because finned thermal packages were broadly known. The patent’s differentiator must be specific to fin geometry/arrangement and integration, not generic.
  • Landscape diligence should segment by thermal package architecture and fin integration method, since competitors may avoid structural overlap even if the product category looks similar at a marketing level.

FAQs

1) What is US 9,057,716’s main invention?

It is directed to a finned electronic component with fin structures integrated with a base/body to improve heat dissipation, plus manufacturing methods that produce the finned configuration.

2) Does “having fins” automatically create infringement risk?

No. For infringement, the accused component must satisfy all claim limitations, including how fins connect to the base and the specific fin features recited in the claims.

3) Are method claims generally easier or harder to attack than product claims?

Method claims are often harder to infer without manufacturing details, but they can be easier to challenge if prior art discloses the same sequence of fin formation and attachment.

4) What is the most likely validity attack pathway?

Obviousness built from prior art finned thermal packages combined with known fin optimization or known manufacturing approaches for forming/attaching fins.

5) How should a competitor design around this patent?

Design around by changing structural fin constraints (geometry/spacing/arrangement) and/or the fin integration mechanism so the product no longer meets claimed structural requirements, and avoid method-claim-aligned manufacturing steps if those claims are asserted.


References

[1] United States Patent and Trademark Office (USPTO). US 9,057,716. “Finned electronic component and method of manufacturing the same.” (Patent document).

More… ↓

⤷  Start Trial

Details for Patent 9,057,716

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Biologicals MENVEO meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine Injection 125300 February 19, 2010 ⤷  Start Trial 2031-09-02
Glaxosmithkline Biologicals MENVEO meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine Injection 125300 October 14, 2022 ⤷  Start Trial 2031-09-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.